The newly-founded Oxford cardiovascular imaging spinout raised seed funding from backers including Oxford Sciences Innovation to pursue further product development.
Caristo Diagnostics, a UK-based cardiovascular imaging software spinout from University of Oxford, launched publicly yesterday with £2m ($2.6m) of seed money from investors including Oxford Sciences Innovation, the university’s venturing fund.
The round also featured Oxford Technology Investment Fund and venture capital firm Longwall Ventures.
Founded in June 2018, Caristo Diagnostics is working on imaging software that locates inflammation in fat tissues encompassing the coronary arteries which act as early indicators of serious complications including heart failure and stroke.
The software relies on biomarkers on images from computed tomography angiograms, an existing clinical examination used to catch blockages, to quantify the inflammation according to a so-called Fat Attenuation Index (FAI) that estimates the patient’s residual cardiovascular risk.
Caristo’s product will be sold through a software-as-a-service model and is expected to act as a companion diagnostic tool for both healthcare providers and biopharmaceutical developers. The seed capital…
